Pionyr Immunotherapeutics Is A Clinical Stage Biotechnology Company Based In South San Franciscocaliforniafounded In 2015The Company Focuses On Developing Innovative Cancer Immunotherapies That Target The Tumor Microenvironment To Enhance The Body S Antitumor Immunityin August 2023Pionyr Was Acquired By Ikena Oncology In An All Stock Transaction The Company Specializes In Creating Monoclonal Antibodies That Reprogram Immune Cells Within Tumorsshifting The Microenvironment From Immunosuppressive To Immune Activatingpionyr Utilizes Proprietary Platforms For Novel Target Discovery And Antibody Generationaiming To Identify Myeloid Cell Targets That Play A Crucial Role In Immune Evasionwith A Total Funding Of $345 Million Prior To Its Acquisitionpionyr Is Dedicated To Advancing Its Clinical Stage Candidates In The Field Of Immuno Oncology
No conferences found for this company.
| Company Name | Pionyr Immunotherapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
